In Vitro Effects of Omeprazole in Combination with Antifungal Compounds Against Malassezia Pachydermatis

Overview

Journal Vet Med Sci

Specialty Veterinary Medicine

Date 2023 Oct 24

PMID 37872836

Authors

Juyoung Shin

Seulgi Bae

Affiliations

Soon will be listed here.

Abstract

Background: Fungal and yeast infections, including those caused by Malassezia spp., are becoming increasingly difficult to treat, likely due to the occurrence of drug resistance.

Objectives: This study aimed to evaluate the antifungal effects of omeprazole (OME), a proton pump inhibitor, against antifungal-resistant Malassezia pachydermatis and to investigate the potential synergistic effects between OME and other antifungal compounds.

Methods: In total, 15 samples of M. pachydermatis isolated from the skin of dogs were tested. The susceptibility of M. pachydermatis to itraconazole, ketoconazole, miconazole, terbinafine and OME was assessed using a modified broth microdilution (BM) method. The in vitro efficacy of OME alone and in combination with other antifungal compounds was evaluated for all isolates using the BM chequerboard method. The data obtained were analysed using the fractional inhibitory concentration index (FICI).

Results: The minimum inhibitory concentration (MIC) values of antifungal compounds and OME against quality control strain (M. pachydermatis CBS1879) were lower than the MIC values of same drugs against clinically collected strains. There was no significant difference in MIC values between drugs alone and combination. According to the analysis by the FICI method, no interaction was observed with OME and antifungal compounds.

Conclusions: Most M. pachydermatis strains were resistant to azole antifungal compounds. OME exerted antifungal effects against Malassezia spp. and even showed good effects on antifungal-resistant strains. No synergistic effects were observed between the antifungal compounds and OME.

Citing Articles

In vitro effects of omeprazole in combination with antifungal compounds against Malassezia pachydermatis.

Shin J, Bae S Vet Med Sci. 2023; 9(6):2594-2599.

PMID: 37872836 PMC: 10650238. DOI: 10.1002/vms3.1305.

References

Lu M, Yan H, Yu C, Yuan L, Sun S . Proton pump inhibitors act synergistically with fluconazole against resistant Candida albicans. Sci Rep. 2020; 10(1):498. PMC: 6965112. DOI: 10.1038/s41598-019-57174-4. View

Morris D . Malassezia dermatitis and otitis. Vet Clin North Am Small Anim Pract. 1999; 29(6):1303-10. DOI: 10.1016/s0195-5616(99)50128-9. View

Guillot J, Bensignor E, Jankowski F, Seewald W, Chermette R, Steffan J . Comparative efficacies of oral ketoconazole and terbinafine for reducing Malassezia population sizes on the skin of Basset Hounds. Vet Dermatol. 2003; 14(3):153-7. DOI: 10.1046/j.1365-3164.2003.00334.x. View

Odds F . Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003; 52(1):1. DOI: 10.1093/jac/dkg301. View

Uchida Y, Onodera S, Nakade T, Otomo K . Sterol composition in polyene antibiotic-sensitive and resistant strains of Malassezia pachydermatis. Vet Res Commun. 1994; 18(3):183-7. DOI: 10.1007/BF01839267. View

Bond R, Morris D, Guillot J, Bensignor E, Robson D, Mason K . Biology, diagnosis and treatment of Malassezia dermatitis in dogs and cats Clinical Consensus Guidelines of the World Association for Veterinary Dermatology. Vet Dermatol. 2020; 31(1):28-74. DOI: 10.1111/vde.12809. View

Afeltra J, Vitale R, Mouton J, Verweij P . Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother. 2004; 48(4):1335-43. PMC: 375285. DOI: 10.1128/AAC.48.4.1335-1343.2004. View

Pfaller M . Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2011; 125(1 Suppl):S3-13. DOI: 10.1016/j.amjmed.2011.11.001. View

El-Ganiny A, Kamel H, Yossef N, Mansour B, El-Baz A . Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical and non-albicans isolates. Saudi Pharm J. 2022; 30(3):245-255. PMC: 9051972. DOI: 10.1016/j.jsps.2022.01.011. View

10.

Angileri M, Pasquetti M, De Lucia M, Peano A . Azole resistance of causing treatment failure in a dog. Med Mycol Case Rep. 2019; 23:58-61. PMC: 6325069. DOI: 10.1016/j.mmcr.2018.12.004. View

11.

Watanabe S, Koike A, Kano R, Nagata M, Chen C, Hwang C . In vitro susceptibility of Malassezia pachydermatis isolates from canine skin with atopic dermatitis to ketoconazole and itraconazole in East Asia. J Vet Med Sci. 2013; 76(4):579-81. PMC: 4064146. DOI: 10.1292/jvms.13-0433. View

12.

Peano A, Johnson E, Chiavassa E, Tizzani P, Guillot J, Pasquetti M . Antifungal Resistance Regarding : Where Are We Now?. J Fungi (Basel). 2020; 6(2). PMC: 7345795. DOI: 10.3390/jof6020093. View

13.

Shin J, Bae S . In vitro effects of omeprazole in combination with antifungal compounds against Malassezia pachydermatis. Vet Med Sci. 2023; 9(6):2594-2599. PMC: 10650238. DOI: 10.1002/vms3.1305. View

14.

Cafarchia C, Iatta R, Immediato D, Puttilli M, Otranto D . Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values. Med Mycol. 2015; 53(7):743-8. DOI: 10.1093/mmy/myv049. View

15.

Nijima M, Kano R, Nagata M, Hasegawa A, Kamata H . An azole-resistant isolate of Malassezia pachydermatis. Vet Microbiol. 2010; 149(1-2):288-90. DOI: 10.1016/j.vetmic.2010.10.010. View

16.

Cafarchia C, Figueredo L, Favuzzi V, Surico M, Colao V, Iatta R . Assessment of the antifungal susceptibility of Malassezia pachydermatis in various media using a CLSI protocol. Vet Microbiol. 2012; 159(3-4):536-40. DOI: 10.1016/j.vetmic.2012.04.034. View

17.

Uchida Y, Nakade T, Kitazawa K . In vitro activity of five antifungal agents against Malassezia pachydermatis. Nihon Juigaku Zasshi. 1990; 52(4):851-3. DOI: 10.1292/jvms1939.52.851. View

18.

Iatta R, Puttilli M, Immediato D, Otranto D, Cafarchia C . The role of drug efflux pumps in Malassezia pachydermatis and Malassezia furfur defence against azoles. Mycoses. 2016; 60(3):178-182. DOI: 10.1111/myc.12577. View

19.

Chen T, Hill P . The biology of Malassezia organisms and their ability to induce immune responses and skin disease. Vet Dermatol. 2005; 16(1):4-26. DOI: 10.1111/j.1365-3164.2005.00424.x. View

20.

Liu N, Kohler J . Antagonism of Fluconazole and a Proton Pump Inhibitor against Candida albicans. Antimicrob Agents Chemother. 2015; 60(2):1145-7. PMC: 4750695. DOI: 10.1128/AAC.02043-15. View